IDSA GUIDELINES Bundle (free trial)

Outpatient Community-Acquired Pneumonia

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/55272

Contents of this Issue

Navigation

Page 5 of 7

Selecting a Treatment Regimen Table 2. Initial Empirical Antibiotic Therapy for Suspected Bacterial CAP Patient Variable OUTPATIENT Previously healthy No recent antibiotic therapy within previous 3 months, and no risk for drug-resistant S. pneumoniae Comorbidities COPD, diabetes, chronic heart, liver, lung or renal disease, malignancy, alcoholism, asplenia, immunosuppressing conditions or use of immunosuppressive drugs, use of antimicrobials within last 3 months Respiratory fluoroquinolone (moxifloxacin, gemifloxacin, levofloxacin [750 mg† ])* OR β-Lactam (high-dose amoxicillin [1 g tid], or amoxicillin- clavulanate [2 g bid using the 1000 mg/62.5 mg extended- release tablet formulation]), plus a macrolide (doxycycline is an alternative to the macrolide). Alternative β-lactams include ceſtriaxone, cefpodoxime, cefuroxime (500 mg bid)* In regions with a 25% or higher rate of infection with high-level (MIC ≥16 μg/mL) macrolide-resistant S. pneumoniae For any patient, including those without comorbidities Respiratory fluoroquinolone (moxifloxacin, gemifloxacin, levofloxacin [750 mg† ])* OR β-Lactam (high-dose amoxicillin [1 g tid] , or amoxicillin- clavulanate [2 g bid using the 1000 mg/62.5 mg extended- release tablet formulation]), plus a macrolide (doxycycline is an alternative to the macrolide). Alternative β-lactams include ceſtriaxone, cefpodoxime, cefuroxime (500 mg bid)* * If patient received a macrolide in previous 3 months, use a fluoroquinolone and vice versa. † This dose for patients with normal renal function. Table 3. Recommended Antimicrobials for Outpatient Treatment of CAP Antimicrobial Amoxicillin/clavulanate (Augmentin® ) Route β-Lactam/β-lactamase inhibitors PO 2 g bid † mg/62.5 mg extended- release tablet formulation) (using the 1000 > β-Lactams inactive against atypical pathogens > Amoxicillin-clavulanate active against most H. influenzae, methicillin-susceptible S. aureus and anaerobes Adult Dose* Comments Macrolide OR doxycycline Treatment Option (See Table 3 for dosage) > Dose listed is specified for empirical therapy based on presence of risk factors for resistance, lower doses are adequate for penicillin- susceptible S. pneumoniae 4

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Outpatient Community-Acquired Pneumonia